[1]张 鼎,赵 斌.朗格汉斯组织细胞增生症的诊治进展[J].医学信息,2019,32(19):35-38.[doi:10.3969/j.issn.1006-1959.2019.19.012]
　ZHANG Ding,ZHAO Bin.Progress in the Diagnosis and Treatment of Langerhans Cell Histiocytosis[J].Journal of Medical Information,2019,32(19):35-38.[doi:10.3969/j.issn.1006-1959.2019.19.012]

点击复制

朗格汉斯组织细胞增生症的诊治进展()

分享到：

参考文献/References:

[1]Horibe K,Saito AM,Takimoto T,et al.Incidence and survival rates of hematological malignancies in Japanese children and adolescents（2006-2010）:based on registry data from the Japanese Society of Pediatric Hematology[J].Int J Hematol,2013,98(1):74-88. [2]Swerdlow SH,Campo E,Pileri SA,et al.WHO classification of tumours of haematopoietic and lymphoid tissues.In:Weiss LM,Jaffe R,Facchetti F,eds.WHO classification of Tumours of Haematopoietic and Lymphoid Tissues[J].Blood,2016,127(20):2375. [3]Badalian-Very G,Vergilio J A,Degar B A,et al.recurrent BRAF mutations in Langerhans cell histiocytosis[J].Blood,2010,116(11):1919-1923． [4]Ozer Erdener,Sevinc Akin,Ince Dilek,et al.BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis[J].Pediatric and developmental pathology,2019,36(1):69-86. [5]Brown NA,Furtado LV,Betz BL,et al.High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis[J].Blood,2014,124(10):1655-1658. [6]Emile JF,Abla O,Fraitag S,et al.Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages[J].Blood,2016,127(22):2672-2681. [7]Tazi A,de Margerie C,Naccache JM,et al.The natural history of adult pulmonary Langerhans cell histiocytosis:a prospective multicentre study[J].Orphanet J Rare Dis,2015,10(3):30. [8]李建红,李萍,唐鹏跃,等.儿童朗格汉斯细胞组织细胞增生症20例临床分析[J].中国皮肤性病学杂志,2018,32(6):650-653. [9]赵丽,赵林胜,苏海辉,等.以皮疹为首发症状的儿童朗格汉斯细胞组织细胞增生症19例临床病理分析[J].临床与实验病理学杂志,2018,34(5):550-552. [10]张丽丽,刘玲,武强,等.15例儿童朗格汉斯细胞组织细胞增生症病理诊断及鉴别诊断[J].河北医科大学学报,2018,39(7):817-821. [11]KobayashiM,TojoA.Langerhans cell histiocytosis in adults:Advances in pathophysiology and treatment[J].Cancer Science,2018,109(12):3707-3713. [12]杨芳,王晓莉.儿童朗格汉斯细胞组织细胞增生症3例并文献复习[J].福建医药杂志,2018,40(5):40-44,182. [13]Tazi A,Lorillon G,Haroche J,et al.Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis:a multicenter retrospective study[J].Orphanet J Rare Dis,2017,12(1):95. [14]刘玉洁,刘炜,陶箐,等.30例高危多系统性朗格汉斯细胞组织细胞增生症的临床病理特征并文献复习[J].临床与病理杂志,2018,38(10):2094-2101. [15]Héritier S,Hélias-Rodzewicz Z,Lapillonne H,et al.Circulating cellfree BRAFV600E as a biomarker in children with Langerhans cell histiocytosis[J].Br J Haematol,2017,178(3):457-467. [16]Simko SJ,McClain KL,Allen CE.Up-front therapy for LCH:is it time to test an alternative to vinblastine/prednisone[J].Br J Haematol,2015,169(2):299-301. [17]Craig Erker,Paul Harker-Murray,Julie-An Talano.Usual and unusual manifestations of familial hemophagocytic lymphohistiocytosis and langerhans cell histiocytosis[J].The Pediatric Clinics of North America,2017,64(1):91-109． [18]Berres ML,Lim KP,Peters T,et al.BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups[J].J Exp Med,2015,212(2):281. [19]Derenzini E,Stefoni V,Pellegrini C,et al.High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis,a 20 year experience[J].BMC Cancer,2015,15(1):879. [20]Veys PA,Nanduri V,Baker KS,et al.Haematopoietic stem cell transplantation for refractory langerhans cell histiocytosis:outcome by intensity of conditioning[J].Br J Haemato,2015,169(5):711-718. [21]Gabalec Filip,imkoviMartin,Zavelová Alběta,et al.Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine,Surgery and Allogenic Stem Cell Transplantation[J].Acta medica,2017,60(4):152-156. [22]闫美玲,张萌,黄琳,等.BRAF V600E抑制剂治疗小儿朗格罕斯组织细胞增生症的临床分析[J].中国新药杂志,2019,28(7):886-890. [23]Diamond EL,Subbiah V,Lockhart AC,et al.Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans CellHistiocytosis:analysis of data from the histology-independent,phase 2,open-label VEBASKET Study[J].JAMA Oncol,2018(4):384-388. [24]Papapanagiotou M,Griewank KG,Hillen U,et al.Trametinibinduced remission of an MEK1-mutated langerhans cell histiocytosis[J].JCO Precis Oncol,2017(1):1-5. [25]Chow TW,Leung WK,Cheng FWT,et al.Late outcomes in children with Langerhans cell histiocytosis[J].Archives of Disease in Childhood,2017,102(9):830-835.